APELLIS PHARMACEUTICALS, INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 706
- Market Cap
- $4.8B
- Website
- http://www.apellis.com
Clinical Trials
65
Trial Phases
3 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- Conditions
- Delayed Graft FunctionDeceased Donor Kidney TransplantEnd Stage Renal Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT07020832
Geographic Atrophy Long-Terms Outcomes Study
- Conditions
- Geographic Atrophy
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT06499571
- Locations
- 🇦🇺
Sydney West Retina, Westmead, New South Wales, Australia
🇫🇷Centre Hospitalier de la Croix Rousse, Lyon Cedex 04, Rhone, France
🇩🇪Universitaetsklinikum Muenster, Münster, Nordrhein Westfalen, Germany
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06161584
- Locations
- 🇺🇸
Illinois Retina Associates (01-035), Fullerton, California, United States
🇺🇸California Retina Consultants (01-026), Bakersfield, California, United States
🇺🇸Retina-Vitreous Associates Medical Group (01-020), Beverly Hills, California, United States
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
- Conditions
- C3 GlomerulopathyDDDMembranoproliferative GlomerulonephritisComplement 3 GlomerulopathyMembranoproliferative Glomerulonephritis (MPGN)IC-MPGNC3 GlomerulonephritisComplement 3 GlomerulonephritisDense Deposit DiseaseImmune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05809531
- Locations
- 🇺🇸
Academic Medical Research Institute (01034), Los Angeles, California, United States
🇺🇸Children's Hospital Colorado (01037), Aurora, Colorado, United States
🇺🇸University of Florida, Department of Pediatric Nephrology (01010), Gainesville, Florida, United States
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
- Conditions
- C3GMembranoproliferative Glomerulonephritis (MPGN)IC-MPGNComplement 3 GlomerulopathyComplement 3 GlomerulonephritisDense Deposit DiseaseDDDC3 GlomerulopathyComplement 3 Glomerulopathy (C3G)C3 Glomerulonephritis
- Interventions
- Other: Placebo
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT05067127
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Keck School of Medicine, University of Southern California, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next